Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of HRS-7249 in patients with hyperlipidemia
CTR20252992Phase 2Active
- Sponsor
- Tuojie Biotech
- Start
- Sep 2025
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hyperlipidemia comparing HRS-7249 with Placebo (2 arms). Primary endpoint: Percent change from baseline in triglycerides. Started Sep 2025; status: active.
02
Drugs
HRS-7249
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on CTR20252992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252992.